STAT+: Arcus’ anti-TIGIT immunotherapy shows ‘encouraging’ tumor response, but likely leaves investors wanting more

Arcus says its anti-TIGIT immunotherapy shows an "encouraging" tumor response, but likely leaves investors wanting more.

Click to view original post